News & Publications
The latest news and publications about Merkel cell carcinoma and merkelcell.org.
This year's 15th annual MMIG meeting was the first MMIG meeting to take place over Zoom and had a record setting number of attendees (104)!
Read more →What makes life-saving discoveries possible? For patients like Peter Stults, they might say researchers and physicians such as those at UW Medicine. For researchers and physicians, they would say the generosity of spirit of people like Peter. Peter’s estate gift to the Seattle Merkel cell carci...
Read more →With philanthropic support, the Nghiem Lab carried out research that has shown that for MCC, narrower surgical margins, when given with radiation, provide excellent protection against local disease recurrence.
Read more →A recent study by the Nghiem Lab, supported by philanthropy, found that a baseline PET-CT scan discovered ‘hidden’ disease in 1 in 6 patients with MCC, dramatically changing their treatment plans.
Read more →We will hold the 2021 Multicenter Merkel Interest Group (MMIG) meeting on Friday, June 4th, 11 am-1 pm EDT / 8 am-10 am PDT via Zoom. Please email [email protected] for an invitation with the zoom details. If you have an interesting topic to present, please let us know as we have a few avai...
Read more →When you get your chance to receive the COVID vaccine, unless there is a specific contraindication, you should do it! Many patients have been asking this very reasonable question. Our team has in every case said to get vaccinated, whether or not the patient is on therapy to alter their immune resp...
Read more →Dear friends of Merkel cell carcinoma research, As we conclude this unprecedented year, I would like to convey Team Merkel’s appreciation of your support. Although it was a challenging year, 2020 was also one of many exciting milestones in Merkel cell research that I am excited to share with yo...
Read more →Take-Home Message Using the National Cancer Database, cases of stage I–III Merkel cell carcinoma (MCC; N=11,119) were sorted into those treated at high treatment center volume (TCV) institutions versus low TVC institutions. At a median follow-up of 28.8 months, the 2-year overall survival was...
Read more →The STAMP trial is currently recruiting participants at sites all across the country. This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resect...
Read more →